MedTrace Logo

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

NCT05536791 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-06-26

No results posted yet for this study

Summary

The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.

The non-interventional study will be conducted in paediatric hospitals or paediatric departments of EEA member states where Venous thromboembolism (VTE) patients of the evaluated age group are treated.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Dabigatran Etexilate (DE)

Dabigatran Etexilate (DE)

Sponsors & Collaborators

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-24
Primary Completion
2024-10-01
Completion
2024-10-01

Countries

  • Germany
  • Netherlands
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536791 on ClinicalTrials.gov